Поздние осложнения у детей, перенесших трансплантацию гемопоэтических стволовых клеток (обзор литературы)
Аннотация
Оценка поздних осложнений у детей, перенесших трансплантацию гемопоэтических стволовых клеток (ТГСК), разработка их комплексной реабилитации и профилактики являются актуальной задачей детской гематологии-онкологии. Ятрогенные расстройства, связанные с трансплантацией, затрагивают большинство органов и систем организма и ухудшают качество жизни ребенка. В обзоре литературы представлены наиболее часто возникающие поздние эффекты, фиксируемые у детей после ТГСК, которые сгруппированы в соответствии с их влиянием на органы и системы ребенка. Показано, что наибольшее внимание должно уделяться иммуноопосредованным поздним эффектам, вопросам иммунореконституции и поражениям сердечно-сосудистой, дыхательной и костно-мышечной систем, вторичному метаболическому синдрому. Отмечено, что в связи с новыми подходами к ТГСК (тотальное облучение тела, лимфодеплеция, посттрансплантационная клеточная терапия и др.) особое внимание требуется уделять вопросам воздействия на иммунную систему ребенка. Важными проблемами являются развитие нейрокогнитивного и психологического дефицитов. Посттрансплантационное ведение пациентов должно включать медицинскую, нейрокогнитивную, академическую, психологическую и социальную помощь по преодолению последствий трансплантации, что диктует необходимость создания национальных клинических рекомендаций по поздним осложнениям ТГСК, которые будут являться основой для совместной работы трансплантационных и реабилитационных центров.
Об авторе
К. И. Киргизов
ФГБУ «Национальный научно-практический центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России
Россия
117997, Москва, ул. Саморы Машела, 1
Россия
117997, Москва, ул. Саморы Машела, 1
Список литературы
1. Румянцев А.Г., Масчан А.А. Трансплантация гемопоэтических стволовых клеток у детей. Руководство для врачей. М.: Медицинское информационное агентство, 2003. 909 с. [Rumyantsev A.G., Maschan A.A. Hematopoietic stem cell transplantation in children. M.: Medical Information Agency, 2003. 909 pp. (In Russ.)].
2. Скоробогатова Е.В., Балашов Д.Н., Дышлевая З.М. и др. Результаты трансплантации гемопоэтических стволовых клеток у детей. Опыт Федерального научно-клинического центра детской гематологии, онкологии и иммунологии на базе Российской детской клинической больницы. Вопросы гематологии/онкологии и иммунопатологии в педиатрии 2007;6(4):29–35. [Skorobogatova E.V., Balashov D.N., Dyshlevaya Z.M. et al. Results of hematopoietic stem cells transplantation in children. Experience gained by the Federal Research Center of Pediatric Hematology, Oncology, and Immunology at Russian Pediatric Clinical Hospital. Voprosy gematologii/onkologii i immunopatologii v pediatrii = Pediatric Hematology/Oncology and Immunopathology 2007;6(4):29–35. (In Russ.)].
3. Володин Н.Н., Касаткин В.Н., Цейтлин Г.Я. и др. Стратегия медико-психолого- социальной реабилитации детей с гематологическими и онкологическими заболеваниями. Онкогематология 2015;1(1):7–15. [Volodin N.N., Kasatkin V.N., Tseitlin G.Ya. Strategy of medical, psychological and social rehabilitation for children with haematological and oncological diseases. Onkogematologiya = Oncohematology 2015; 1(1):7–15. (In Russ.)].
4. Khandelwal P., Emoto C., Fukuda T. et al. A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 2016;22(12):2220–5.
5. Bleyzac N., Cuzzubbo D., Rénard C. et al. Improved outcome of children transplanted for high-risk leukemia by using a new strategy of cyclosporine-based GVHD prophylaxis. Bone Marrow Transplant 2016;51(5): 698–704.
6. Baker K.S., Bresters D., Sande J.E. The burden of cure: long-term side effects following hematopoietic stem cell transplantation (HSCT) in children. Pediatr Clin North Am 2010;57:323–42.
7. Chow E.J., Anderson L., Baker K.S. et al. Late Effects Surveillance Recommendations among Survivors of Childhood Hematopoietic Cell Transplantation: A Children’s Oncology Group Report. Biol Blood Marrow Transplant 2016;22(5):782–95.
8. Armstrong G.T., Chen Y., Yasui Y. et al. Reduction in Late Mortality among 5-Year Survivors of Childhood Cancer. N Engl J Med 2016;374(9):833–42.
9. Landier W., Bhatia S., Eshelman D.A. et al. Development of risk-based guidelines for pediatric cancer survivors: the Children’s Oncology Group Long-Term Follow-Up Guidelines from the Children’s Oncology Group Late Effects Committee and Nursing Discipline. J Clin Oncol 2004;22(24): 4979–90.
10. Baker K.S., Bhatia S., Bunin N. et al. NCI, NHLBI first international consensus conference on late effects after pediatric hematopoietic cell transplantation: state of the science, future directions. Biol Blood Marrow Transplant 2011;17:1424–7.
11. Neven B., Leroy S., Decaluwe H. et al. Long-term outcome after hematopoietic stem cell transplantation of a single-center cohort of 90 patients with severe combined immunodeficiency. Blood 2009;113:4114–24.
12. Allewelt H., El-Khorazaty J., Mendizabal A. et al. Late Effects after Umbilical Cord Blood Transplantation in Very Young Children after Busulfan-Based, Myeloablative Conditioning. Biol Blood Marrow Transplant 2016;22(9):1627–35.
13. Armenian S.H., Sun C.L., Kawashima T. et al. Long-term health-related outcomes in survivors of childhood cancer treated with HSCT versus conventional therapy: a report from the Bone Marrow Transplant Survivor Study (BMTSS) and Childhood Cancer Survivor Study (CCSS). Blood 2011;118: 1413–20.
14. Children’s Oncology Group. Long-term follow-up guidelines for survivors of childhood, adolescent and young adult cancers, Version 4.0. Monrovia, CA: Children’s Oncology Group. Available at: http://www.survivorshipguidelines.org; 2013. Accessed November 1, 2015.
15. Dvorak C.C., Gracia C.R., Sanders J.E. et al. NCI, NHLBI/PBMTC first international conference on late effects after pediatric hematopoietic cell transplantation: endocrine challenges-thyroid dysfunction, growth impairment, bone health, & reproductive risks. Biol Blood Marrow Transplant 2011;17:1725–38.
16. Majhail N.S., Rizzo J.D., Lee S.J. et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012;18:348–71.
17. Landier W., Wallace W.H., Hudson M.M. Long-term follow-up of pediatric cancer survivors: education, surveillance, and screening. Pediatr Blood Cancer 2006;46(2):149–58.
18. Mertens A.C., Yasui Y., Neglia J.P. et al. Late mortality experience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study. J Clin Oncol 2001;19(13):3163–72.
19. Casillas J., Oeffinger K.C., Hudson M.M. et al. Identifying Predictors of Longitudinal Decline in the Level of Medical Care Received by Adult Survivors of Childhood Cancer: A Report from the Childhood Cancer Survivor Study. Health Serv Res 2015;50(4):1021–42.
20. Скворцова Ю.В., Масчан А.А., Делягин В.М. и др. Актуальные вопросы наблюдения, диагностики и реабилитации пациентов на отдаленных сроках после трансплантации гемопоэтических стволовых клеток. Российский журнал детской гематологии и онкологии 2014;1(2):13–8. [Skvortsova Yu.V., Maschan A.A., Delyagin V.M. The follow-up, diagnosis, and rehabilitation of patients in late periods following hematopoietic stem cell transplantation: Topical issues. Rossiyskiy zhurnal detskoy gematologii i onkologii = Russian Journal of Pediatric Hematology and Oncology 2014;1(2):13–8. (In Russ.)].
21. Румянцев А.Г., Володин Н.Н., Касаткин В.Н., Митраков Н.Н. Концепция медицинской, нейро-когнитивной и психолого-социальной реабилитации детей с онкологическими и гематологическими заболеваниями. Вестник восстановительной медицины 2015;(1):65–71. [Rumyantsev A.G., Volodin N.N., Kasatkin V.N., Mitrakov N.N. The concept of health, neuro-cognitive and psycho-social rehabilitation of children with oncohematological diseases. Vestnik vosstanovitelnoy mediciny = Journal of Restorative Medicine & Rehabilitation 2014;1(2):13–8. (In Russ.)].
22. Вашура А.Ю., Володин Н.Н., Румянцев А.Г., Цейтлин Г.Я. Влияние специальной терапии на показатели нутритивного статуса и осложнения в раннем периоде после трансплантации гемопоэтических стволовых клеток у детей. Вопросы практической педиатрии 2016;11(1):7–12. [Vashura A.Yu., Volodin N.N., Rumyantsev A.G., Tseytlin G.Ya. Influence of specialised therapy on the nutritional status parameters and complications in the early period after haemopoietic stem cell transplantation in children. Voprosy prakticheskoy pediatrii = Questions of Practical Pediatrics 2016;11(1):7–12. (In Russ.)].
23. Miano M., Cancedda R., Hartmann O. et al.; EBMT Paediatric Diseases Working Party. Survey on haematopoietic stem cell transplantation for children in Europe. Bone Marrow Transplant 2005;35 Suppl 1:S3–8.
24. Mazzolari E., Forino C., Guerci S. et al. Long-term immune reconstitution and clinical outcome after stem cell transplantation for severe T-cell mmunodeficiency. J Allergy Clin Immunol 2007;120(4):892–9.
25. Dodero A., Carniti C., Raganato A. et al. Haploidentical stem cell transplantation following a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies: post-transplant CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery. Blood 2009;113:4771–9.
26. Oeffinger K.C., Mertens A.C., Sklar C.A. et al. Chronic health conditions in adult survivors of childhood cancer. Childhood Cancer Survivor Study. N Engl J Med 2006;355(15):1572–82.
27. Burman J., Iacobaeus E., Svenningsson A. et al. Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience. J Neurol Neurosurg Psychiatry 2014;85(10):1116–21.
28. Muenzer J., Fisher A. Advances in the treatment of mucopolysaccharidosis type I. N Engl J Med 2004;350:1932–4.
29. Balashov D., Shcherbina A., Maschan M. et al. Single-Center Experience of Unrelated and Haploidentical Stem Cell Transplantation with TCRαβ and CD19 Depletion in Children with Primary Immunodeficiency Syndromes. Biol Blood Marrow Transplant 2015;21(11):1955–62.
30. Fuji S., Kapp M., Einsele H. Challenges to preventing infectious complications, decreasing re-hospitalizations, and reducing cost burden in long-term survivors after allogeneic hematopoietic stem cell transplantation. Semin Hematol 2012;49:10–4.
31. Sahin U., Toprak S.K., Atilla P.A. et al. An overview of infectious complications after allogeneic hematopoietic stem cell transplantation. J Infect Chemother 2016;22(8):505–14.
32. Perkins J.L., Chen Y., Harris A. et al. Infections among long-term survivors of childhood and adolescent cancer: a report from the Childhood Cancer Survivor Study. Cancer 2014;120:2514–21.
33. Tomblyn M., Chiller T., Einsele H. et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009;15(10): 1143–238.
34. Khalaf A.M., Hashim M.A., Alsharabati M. et al. Late-Onset Cerebral Toxoplasmosis After Allogeneic Hematopoietic Stem Cell Transplantation. Am J Case Rep 2017;18:246–50.
35. Carpenter P.A., Englund J.A. How I vaccinate blood and marrow transplant recipients. Blood 2016;127(23):2824–32.
36. Maertens J., Marchetti O., Herbrecht R. et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3–2009 update. Bone Marrow Transplant 2011;46(5):709–18.
37. Asano-Mori Y., Kanda Y., Oshima K. et al. Long-term ultra-low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation. Am J Hematol 2008;83(6):472–6.
38. Shah D.P., Ghantoji S.S., Ariza-Heredia E.J. et al. Immunodeficiency scoring index to predict poor outcomes in hematopoietic cell transplant recipients with RSV infections. Blood 2014;123(21):3263–8.
39. Hsiao H.H., Liu Y.C., Wang H.C. et al. Hepatitis C transmission from viremic donors in hematopoietic stem cell transplant. Transpl Infect Dis 2014;16(6):1003–6.
40. Румянцев А.Г., Аграненко В.А. Клиническая трансфузиология – практическое пособие. М.: Гэотар Медицина, 1997. 575 с. [Rumyantsev A.G., Agranenko V.A. Clinical transfusiology. Practical Benefit. M.: GEOTAR Medicina, 1997. 575 p. (In Russ.)].
41. Armenian S.H., Sun C.L., Vase T. et al. Cardiovascular risk factors in hematopoietic cell transplantation survivors: role in development of subsequent cardiovascular disease. Blood 2012;120:4505–12.
42. Chow E.J., Wong K., Lee S.J. et al. Late cardiovascular complications after hematopoietic cell transplantation. Biol Blood Marrow Transplant 2014;20(6):794–800.
43. van Laar J.M., Farge D., Sont J.K. et al. Autologous hematopoietic stem cell transplantation vs. intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. EBMT/ EULAR Scleroderma Study Group. JAMA 2014;311(24):2490–8.
44. Chow E.J., Chen Y., Kremer L.C. et al. Individual prediction of heart failure among childhood cancer survivors. J Clin Oncol 2015;33:394–402.
45. Liles A., Blatt J., Morris D. et al.; Children’s Oncology Group. Monitoring pulmonary complications in long-term childhood cancer survivors: guidelines for the primary care physician. Cleve Clin J Med 2008;75:531–9.
46. Silva E.G., Paula C.R., de Assis Baroni F., Gambale W. Voriconazole, combined with amphotericin B, in the treatment for pulmonary cryptococcosis caused by C. neoformans (serotype A) in mice with severe combined immunodeficiency (SCID). Mycopathologia 2012;173(5–6):445–9.
47. Gower W.A., Collaco J.M., Mogayzel P.J. Jr. Pulmonary dysfunction in pediatric hematopoietic stem cell transplant patients: non-infectious and long-term complications. Pediatr Blood Cancer 2007;49:225–33.
48. Uhlving H.H., Buchvald F., Heilmann C.J. et al. Bronchiolitis obliterans after allo-SCT: clinical criteria and treatment options. Bone Marrow Transplant 2012;47(8):1020–9.
49. Rodríguez M.L., Martín M.M., Padellano L.C. et al. Gastrointestinal toxicity associated to radiation therapy. Clin Transl Oncol 2010;12:554–61.
50. Hawkey C.J. Hematopoietic Stem Cell Transplantation in Crohn’s Disease: State-of-theArt Treatment. Dig Dis 2017;35(1–2):107–14.
51. Castellino S., Muir A., Shah A. et al. Hepatobiliary late effects in survivors of childhood and adolescent cancer: a report from the Children’s Oncology Group. Pediatr Blood Cancer 2010;54:663–9.
52. Effinger K.E., Migliorati C.A., Hudson M.M. et al. Oral and dental late effects in survivors of childhood cancer: a Children’s Oncology Group report. Support Care Cancer 2014;22(7):2009–19.
53. Jensen S.B., Pedersen A.M., Vissink A. et al. A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life. Support Care Cancer 2010;18:1039–60.
54. Selwitz R.H., Ismail A.I., Pitts N.B. Dental caries. Lancet 2007;369:51–9.
55. Dahllöf G., Wondimu B., Barr-Agholme M. et al. Xerostomia in children and adolescents after stem cell transplantation conditioned with total body irradiation or busulfan. Oral Oncol 2011;47(9):915–9.
56. Kida A., McDonald G.B. Gastrointestinal, hepatobiliary, pancreatic, and iron-related diseases in long-term survivors of allogeneic hematopoietic cell transplantation. Semin Hematol 2012;49(1):43–58.
57. McDonald G.B. Hepatobiliary complications of hematopoietic cell transplantation, 40 years on. Hepatology 2010;51:1450–60.
58. Qiao J., Huang Y., Xia Y. et al. Busulfan and cyclosphamide induce liver inflammation through NLRP3 activation in mice after hematopoietic stem cell transplantation. Sci Rep 2015;5:17828.
59. Myers K.C., Dandoy C., El-Bietar J. et al. Veno-occlusive disease of the liver in the absence of elevation in bilirubin in pediatric patients after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2015;21(2):379–81.
60. Au W.Y., Lam W.M., Chu W.C. et al. A magnetic resonance imaging study of iron overload in hemopoietic stem cell transplant recipients with increased ferritin levels. Transplant Proc 2007;39(10):3369–74.
61. Jones D.P., Spunt S.L., Green D., Springate J.E. Renal late effects in patients treated for cancer in childhood: a report from the Children’s Oncology Group. Pediatr Blood Cancer 2008;51:724–31.
62. Hingorani S.R., Seidel K., Lindner A. et al. Albuminuria in hematopoietic cell transplantation patients: prevalence, clinical associations, and impact on survival. Biol Blood Marrow Transplant 2008;14:1365–72.
63. Martires K.J., Baird K., Steinberg S.M. et al. Sclerotic-type chronic GVHD of the skin: clinical risk factors, laboratory markers, and burden of disease. Blood 2011;118:4250–7.
64. Notarangelo L.D., Fischer A., Geha R.S. et al. Primary immunodeficiencies: 2009 update. J Allergy Clin Immunol 2009;124(6):1161–78.
65. Gassas A., Sung L., Dupuis A. et al. Acute gut GVHD in children: does skin involvement matter? Bone Marrow Transplant 2013;48(8):1129–32.
66. Barrett M.J., Buckley R.H., Schiff S.E. et al. Accelerated development of immunity following transplantation of maternal marrow stem cells into infants with severe combined immunodeficiency and transplacentally acquired lymphoid chimerism. Clin Exp Immunol 1988;72:118–23.
67. Wagner J.E., MacMillan M.L., Auerbach A.D. Hematopoietic cell transplantation for Fanconi anemia. In: Blume K.G., Forman S.J., Appelbaum F.R., eds. Hematopietic cell transplantation. 3rd ed. Malden, MA: Blackwell Sciences, 2004. Pp. 1483–1504.
68. Petryk A., Polgreen L.E., Zhang L. et al. Bone mineral deficits in recipients of hematopoietic cell transplantation: the impact of young age at transplant. Bone Marrow Transplant 2014;49:258–63.
69. Greer F.R., Krebs N.F. Optimizing bone health and calcium intakes of infants, children, and adolescents. Pediatrics 2006;117:578–85.
70. Petryk A., Bergemann T.L., Polga K.M. et al. Prospective study of changes in bone mineral density and turnover in children after hematopoietic cell transplantation. J Clin Endocrinol Metab 2006;91:899–905.
71. Le Meignen M., Auquier P., Barlogis V. et al. Bone mineral density in adult survivors of childhood acute leukemia: impact of hematopoietic stem cell transplantation and other treatment modalities. Blood 2011;118:1481–9.
72. Li X., Brazauskas R., Wang Z. et al. Avascular necrosis of bone after allogeneic hematopoietic cell transplantation in children and adolescents. Biol Blood Marrow Transplant 2014;20:587–92.
73. Schmidt M., Breyer S., Löbel U. et al. Musculoskeletal manifestations in mucopolysaccharidosis type I (Hurler syndrome) following hematopoietic stem cell transplantation. Orphanet J Rare Dis 2016;11(1):93.
74. Masterson E.L., Murphy P.G., O’Meara A. et al. Hip dysplasia in Hurler’s syndrome: orthopaedic management after bone marrow transplantation. J Pediatr Orthop 1996;16:731–3.
75. Ruble K., Hayat M.J., Stewart K.J., Chen A.R. Bone mineral density after bone marrow transplantation in childhood: measurement and associations. Biol Blood Marrow Transplant 2010;16:1451–7.
76. Chow E.J., Liu W., Srivastava K. et al. Differential effects of radiotherapy on growth and endocrine function among acute leukemia survivors: a childhood cancer survivor study report. Pediatr Blood Cancer 2013;60:110–5.
77. Vogelius I.R., Bentzen S.M., Maraldo M.V. et al. Risk factors for radiation-induced hypothyroidism: a literature-based meta-analysis. Cancer 2011;117(23):5250–60.
78. Yaglova N.V., Sledneva Y.P., Yaglov V.V. Morphofunctional Changes in the Thyroid Gland of Pubertal and Postpubertal Rats Exposed to Low Dose of DDT. Bull Exp Biol Med 2016;162(2):260–3.
79. Ergun-Longmire B., Mertens A.C., Mitby P. et al. Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor. J Clin Endocrinol Metab 2006;91:3494–8.
80. Patterson B.C., Chen Y., Sklar C.A. et al. Growth hormone exposure as a risk factor for the development of subsequent neoplasms of the central nervous system: a report from the childhood cancer survivor study. J Clin Endocrinol Metab 2014;99:2030–7.
81. Baker K.S., Chow E., Steinberger J. Metabolic syndrome and cardiovascular risk in survivors after hematopoietic cell transplantation. Bone Marrow Transplant 2012;47:619–25.
82. Metzger M.L., Meacham L.R., Patterson B. et al. Female reproductive health after childhood, adolescent, and young adult cancers: guidelines for the assessment and management of female reproductive complications. J Clin Oncol 2013;31:1239–47.
83. Gurney J.G., Ness K.K., Rosenthal J. et al. Visual, auditory, sensory, and motor impairments in long-term survivors of hematopoietic stem cell transplantation performed in childhood: results from the Bone Marrow Transplant Survivor study. Cancer 2006;106:1402–8.
84. Horwitz M., Auquier P., Barlogis V. et al. Incidence and risk factors for cataract after haematopoietic stem cell transplantation for childhood leukaemia: an LEA study. Br J Haematol 2015;168:518–25.
85. Grewal S., Merchant T., Reymond R. et al. Auditory late effects of childhood cancer therapy: a report from the Children’s Oncology Group. Pediatrics 2010;125:e938–e950.
86. Fahnehjelm K.T., Tornquist A.L., Olsson M., Winiarski J. Visual outcome and cataract development after allogeneic stem-cell transplantation in children. Acta Ophthalmol Scand 2007;85:724–33.
87. Bertolini P., Lassalle M., Mercier G. et al. Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss. J Pediatr Hematol Oncol 2004;26:649–55.
88. Merchant T.E., Gould C.J., Xiong X. et al. Early neuro-otologic effects of three-dimensional irradiation in children with primary brain tumors. Int J Radiat Oncol Biol Phys 2004;58:1194–207.
89. Kadan-Lottick N.S., Zeltzer L.K., Liu Q. et al. Neurocognitive functioning in adult survivors of childhood non-central nervous system cancers. J Natl Cancer Inst 2010;102:881–93.
90. Willard V.W., Leung W., Huang Q. et al. Cognitive outcome after pediatric stem-cell transplantation: impact of age and total-body irradiation. J Clin Oncol 2014;32:3982–8.
91. Syrjala K.L., Artherholt S.B., Kurland B.F. et al. Prospective neurocognitive function over 5 years after allogeneic hematopoietic cell transplantation for cancer survivors compared with matched controls at 5 years. Clin Oncol 2011;29(17):2397–404.
92. Lajiness-O’Neill R., Hoodin F., Kentor R. et al. Alterations in Memory and Impact on Academic Outcomes in Children Following Allogeneic Hematopoietic Cell Transplantation. Arch Clin Neuropsychol 2015;30(7):657–69.
93. Danner-Koptik K.E., Majhail N.S., Brazauskas R. et al. Second malignancies after autologous hematopoietic cell transplantation in children. Bone Marrow Transplant 2013;48:363–8.
94. Krishnan A., Bhatia S., Slovak M.L. et al. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood 2000;95:1588–93.
95. Curtis R.E., Travis L.B., Rowlings P.A. et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 1999;94:2208–16.
96. Rowlings P.A., Curtis R.E., Passweg J.R. et al. Increased incidence of Hodgkin’s disease after allogeneic bone marrow transplantation. J Clin Oncol 1999;17:3122–7.
97. Pole J.D., Darmawikarta D., Gassas A. et al. Subsequent malignant neoplasms in pediatric cancer patients treated with and without hematopoietic SCT. Bone Marrow Transplant 2015;50:721–6.
98. Waterman J., Rybicki L., Bolwell B. et al. Fludarabine as a risk factor for poor stem cell harvest, treatment-related MDS and AML in follicular lymphoma patients after autologous hematopoietic cell transplantation. Bone Marrow Transplant 2012;47(4):488–93.
99. Deol A., Abrams J., Masood A. et al. Long-term follow up of patients proceeding to transplant using plerixafor mobilized stem cells and incidence of secondary myelodysplastic syndrome/AML. Bone Marrow Transplant 2013;48(8):1112–6.
100. Nieder M.L., McDonald G.B., Kida A. et al. National Cancer Institute-National Heart, Lung and Blood Institute/pediatric Blood and Marrow Transplant Consortium First International Consensus Conference on late effects after pediatric hematopoietic cell transplantation: long-term organ damage and dysfunction. Biol Blood Marrow Transplant 2011;17:1573–84.
Для цитирования:
Киргизов К.И. Поздние осложнения у детей, перенесших трансплантацию гемопоэтических стволовых клеток (обзор литературы). Российский журнал детской гематологии и онкологии (РЖДГиО). 2017;4(2):29-39. https://doi.org/10.17650/2311-1267-2017-4-2-29-39
For citation:
Kirgizov K.I. Late effects in children who underwent hematopoietic stem cell transplantation (review). Russian Journal of Pediatric Hematology and Oncology. 2017;4(2):29-39. (In Russ.) https://doi.org/10.17650/2311-1267-2017-4-2-29-39
Просмотров: 236
Послать статью по эл. почте 